On August 27th, 2022, the annual meeting of the Ophthalmology Professional Committee of the China Medical Equipment Association and the Chinese Journal of Ophthalmology (electronic version) and the Ophthalmic Industry Technology and Equipment Exhibition were successfully held online. Nearly 100 well-known experts in the ophthalmology field, scholars from medical schools, executives of medical companies and leaders of medical investment companies were invited to share their clinical experience, explore research technologies and analyze industry trends.
As an influential company in the field of ophthalmic imaging artificial intelligence, Big Vision Medical was invited to participate in this conference. Professor Chen Xinjian, the founder, provided a detailed introduction to the latest research achievements of artificial intelligence in the field of ophthalmic OCT and the transformational application results of Beigene Medical to the attendees.
During the meeting, the honorary titles of the Ophthalmology Professional Committee of the China Medical Equipment Association and the Chinese Journal of Ophthalmology (electronic version) in 2022 were awarded. Big Vision’s fully automated artificial intelligence ophthalmic optical coherence tomography won the honorary title of “Ophthalmic Technology Progress.”
Optical Coherence Tomography (OCT) is an important diagnostic device for major eye diseases in ophthalmology. For a long time, the domestic OCT market mainly relied on imported brands, and the equipment was expensive. At the same time, traditional OCT examination requires operators to manipulate the handle to find and align the pupil of the eye, and press the capture button after judging the signal strength manually. The image quality is greatly affected by the operator’s professional level and actual experience, and there is a large subjective difference in the shooting. After the OCT image is captured, it needs to be read by high-level professional doctors to give a diagnosis. However, the huge number of patients with ophthalmic diseases in China and the severe shortage of ophthalmic medical resources in primary medical institutions have greatly limited the application and popularization of OCT in primary hospitals.
Since its establishment, Big Vision Medical Technology has been focusing on the research and development, manufacturing of AI analysis and diagnostic systems for ophthalmic diseases. With solid scientific research strength, Big Vision Medical Technology was the first to develop and complete an OCT multimodal ophthalmic imaging diagnosis system. The new generation of fully automatic AI OCT (BV1000) independently developed by Big Vision Medical Technology is different from traditional OCT. It realizes automatic pupil positioning and focusing, full-process voice guidance, and can provide auxiliary diagnostic opinions for 16 major fundus diseases. The equipment’s “smart, accurate, and efficient” characteristics have been fully tested in clinical applications. Currently, Big Vision BV1000 equipment has cooperated with more than 100 hospitals across the country. Its product performance fully meets clinical auxiliary diagnostic needs and has received unanimous praise from doctors and users.
Big Vision independently developed fully automatic AI OCT device has been selected to receive the “Ophthalmic Technology Progress” honorary title, which is affirmation of Big Vision Medical Technology’s commitment and technical strength in the ophthalmic imaging AI field. Furthermore, it is also a driving force for Big-eyes’ future. Big Vision will gather momentum and work hard to achieve more breakthroughs from “zero to one”, effectively enhance the company’s independent innovation capabilities, engage in the technology for good, and bring brightness and benefits to the people.
No comments yet.